Roles of FGFR2 and twist in human craniosynostosis: Insights from genetic mutations in cranial osteoblasts

Frontiers of Oral Biology

Volumn 12, Issue , 2008, Pages 144-159

  Marie, Pierre J ^a,b   Kaabeche, Karim ^a   Guenou, Hind ^a  

^a UNIVERSITÉ PARIS DESCARTES   (France)

^b HÔPITAL LARIBOISIÈRE   (France)

Author keywords

[No Author keywords available]

Indexed keywords

FGFR2 PROTEIN, HUMAN; FIBROBLAST GROWTH FACTOR RECEPTOR 2; NUCLEAR PROTEIN; TRANSCRIPTION FACTOR TWIST; TWIST1 PROTEIN, HUMAN;

CRANIAL SUTURE; CRANIOFACIAL SYNOSTOSIS; CYTOLOGY; GENETICS; HUMAN; MUTATION; OSTEOBLAST; PHENOTYPE; PHYSIOLOGY; REVIEW; SKULL; SYNDROME;

CRANIAL SUTURES; CRANIOSYNOSTOSES; HUMANS; MUTATION; NUCLEAR PROTEINS; OSTEOBLASTS; PHENOTYPE; RECEPTOR, FIBROBLAST GROWTH FACTOR, TYPE 2; SKULL; SYNDROME; TWIST TRANSCRIPTION FACTOR;

EID: 45849105613     PISSN: 14202433     EISSN: 16623770     Source Type: Book Series    
DOI: 10.1159/000115036     Document Type: Article

References (76)

1. Hall BK, Miyake T: All for one and one for all: condensations and the initiation of skeletal development. Bioessays 2000;22:138-147. (Pubitemid 30092080)
2. Opperman LA: Cranial sutures as intramembranous bone growth sites. Dev Dyn 2000;219:472-485.
3. Cohen MM Jr: Perspectives on craniosynostosis. Am J Med Genet A 2005;136:313-326.
4. Marie PJ: The molecular genetics of bone formation: implications for therapeutic interventions in bone disorders. Am J Pharmacogenomics 2001;1:175-187.
5. Karsenty G, Wagner EF: Reaching a genetic and molecular understanding of skeletal development. Dev Cell 2002;2:389-406. (Pubitemid 34436569)
6. Greenwald JA, Mehrara BJ, Spector JA, Warren SM, Fagenholz PJ, Smith LE, Bouletreau PJ, Crisera FE, Ueno H, Longaker MT: In vivo modulation of FGF biological activity alters cranial suture fate. Am J Pathol 2001;158:441-452. (Pubitemid 32158607)
7. Kim H-J, Rice DPC, Kettunen PJ, Thesleff I: FGF-, BMP-and Shh-mediated signaling pathways in the regulation of cranial suture morphogenesis and calvaria bone development. Development 1998;125:1241-1251. (Pubitemid 28203938)
8. Morriss-Kay GM, Iseki S, Johnson D: Genetic control of the cell proliferation-differentiation balance in the developing skull vault: roles of fibroblast growth factor receptor signaling pathways. Novartis Found Symp 2001;232:102-116.
9. Dailey L, Ambrosetti D, Mansukhani A, Basilico C: Mechanisms underlying differential responses to FGF signaling. Cytokine Growth Factor Rev 2005;16:233-247. (Pubitemid 40616120)
10. Lenton KA, Nacamuli RP, Wan DC, Helms JA, Longaker MT: Cranial suture biology. Curr Top Dev Biol 2005;66:287-328. (Pubitemid 43588842)
11. Marie PJ, Debiais F, Hay E: Regulation of human cranial osteoblast phenotype by FGF-2, FGFR-2 and BMP-2 signaling. Histol Histopathol 2002;17:877-885. (Pubitemid 34784671)
12. de Pollak C, Arnaud E, Renier D, Marie PJ: Age-related changes in bone formation, osteoblastic cell proliferation, and differentiation during postnatal osteogenesis in human calvaria. J Cell Biochem 1997;64:128-139. (Pubitemid 27081800)
13. Lomri A, de Pollak C, Sebag M, Goltzman D, Kremer R, Marie PJ: Expression of parathyroid hormone-related peptide (PTHrP) and PTH/PTHrP receptor in newborn human calvaria osteoblastic cells. Eur J Endocrinol 1997;136:640-648. (Pubitemid 27286552)
14. Debiais F, Hott M, Graulet AM, Marie PJ: The effects of fibroblast growth factor-2 on human neonatal calvaria osteoblastic cells are differentiation stage specific. J Bone Miner Res 1998;13:645-654. (Pubitemid 28163015)
15. Hay E, Hott M, Graulet AM, Lomri A, Marie PJ: Effects of bone morphogenetic protein-2 on human neonatal calvaria cell differentiation. J Cell Biochem 1999;72:81-93. (Pubitemid 28541483)
16. De Pollack C, Renier D, Hott M, Marie PJ: Increased bone formation and osteoblastic cell phenotype in premature cranial suture ossification (craniosynostosis). J Bone Miner Res 1996;11:401-407. (Pubitemid 26076390)
17. Shevde NC, Bendixen A, Maruyama M, Li BL, Billmire DA: Enhanced activity of osteoblast differentiation factor (PEBP2alphaA2/CBFa1) in affected sutural osteoblasts from patients with nonsyndromic craniosynostosis. Cleft Palate Craniofac J 2001;38:606-614. (Pubitemid 33072107)
18. Lomri A, Lemonnier J, Hott M, de Perseval N, Lajeunie E, Munnich A, Renier D, Marie PJ: Increased calvaria cell differentiation and bone matrix formation induced by fibroblast growth factor receptor-2 mutations in Apert syndrome. J Clin Invest 1998;101:1310-1317. (Pubitemid 28145247)
19. Yousfi M, Lasmoles F, Lomri A, Delannoy P, Marie PJ: Increased bone formation and decreased osteocalcin expression induced by reduced Twist dosage in the Saethre-Chotzen syndrome. J Clin Invest 2001;107:1153-1161. (Pubitemid 32422912)
20. Ornitz DM, Marie PJ: FGF signaling pathways in endochondral and intramembranous bone development and human genetic disease. Genes Dev 2002;16:1446-1465. (Pubitemid 34686327)
21. Ornitz DM: FGF signaling in the developing endochondral skeleton. Cytokine Growth Factor Rev 2005;16:205-213. (Pubitemid 40616117)
22. Wilkie AO: Bad bones, absent smell, selfish testes: the pleiotropic consequences of human FGF receptor mutations. Cytokine Growth Factor Rev 2005;16:187-203. (Pubitemid 40616116)
23. Anderson J, Burns HD, Enriquez-Harris P, Wilkie AOM, Heath JK: Apert syndrome mutations in fibroblast growth factor receptor 2 exhibit increased affinity for FGF ligand. Hum Mol Gen 1998;7:1475-1483. (Pubitemid 28429929)
24. Robertson SC, Meyer AN, Hart KC, Galvin BD, Webster MK, Gonoghue DJ: Activating mutations in the extracellular domain of the fibroblast growth factor 2 function by disruption of the disulfide bond in the third immunoglobulin-like domain. Proc Natl Acad Sci USA 1998;95:4567-4572. (Pubitemid 28207953)
25. Plotnikov AN, Hubbard SR, Schlessinger J, Mohammadi M: Crystal structures of two FGF-FGFR complexes reveal the determinants of ligand-receptor specificity. Cell 2000;101:413-424.
26. Ibrahimi OA, Eliseenkova AV, Plotnikov AN, Yu K, Ornitz DM, Mohammadi M: Structural basis for fibroblast growth factor receptor 2 activation in Apert syndrome. Proc Natl Acad Sci USA 2001;98:7182-7187. (Pubitemid 32567923)
27. Yu K, Herr AB, Waksman G, Ornitz DM: Loss of fibroblast growth factor receptor 2 ligand-binding specificity in Apert syndrome. Proc Natl Acad Sci USA 2000;97:14536-14541. (Pubitemid 32016611)
28. Yu K, Ornitz DM: Uncoupling fibroblast growth factor receptor 2 ligand binding specificity leads to Apert syndrome-like phenotypes. Proc Natl Acad Sci USA 2000;98:3641-3643.
29. Hurley MM, Marie PJ, Florkiewicz R: Fibroblast growth factor and fibroblast growth factor receptor families in bone; in Bilezikian J, Raisz LG, Rodan G (eds): Principles of Bone Biology. New York, Academic Press, 2002, pp 825-851.
30. Marie PJ: Fibroblast growth factor signaling controlling osteoblast differentiation. Gene 2003;316:23-32. (Pubitemid 37258340)
31. Mansukhani A, Bellosta P, Sahni M, Basilico C: Signaling by fibroblast growth factors (FGF) and fibroblast growth factor receptor 2 (FGFR-2)-activating mutations blocks mineralization and induces apoptosis in osteoblasts. J Cell Biol 2000;149:1297-1308. (Pubitemid 30399682)
32. Zhou YX, Xu X, Chen L, Li C, Brodie SG, Deng CX: A Pro250Arg substitution in mouse Fgfr1 causes increased expression of Cbfa1 and premature fusion of calvarial sutures. Hum Mol Genet 2000;12:2001-2008. (Pubitemid 30642665)
33. Eswarakumar VP, Monsonego-Ornan E, Pines M, Antonopoulou I, Morriss-Kay GM, Lonai P: The IIIc alternative of Fgfr2 is a positive regulator of bone formation. Development 2002;129:3783-3793. (Pubitemid 34994009)
34. Chen L, Li D, Li C, Engel A, Deng CX: A Ser250Trp substitution in mouse fibroblast growth factor receptor 2 (Fgfr2) results in craniosynostosis. Bone 2003;33:169-178. (Pubitemid 37117129)
35. Yu K, Xu J, Liu Z, Sosic D, Shao J, Olson EN, Towler DA, Ornitz DM: Conditional inactivation of FGF receptor 2 reveals an essential role for FGF signaling in the regulation of osteoblast function and bone growth. Development 2003;130:3063-3074. (Pubitemid 36857252)
36. Eswarakumar VP, Horowitz MC, Locklin R, Morriss-Kay GM, Lonai P: A gain-of-function mutation of Fgfr2c demonstrates the roles of this receptor variant in osteogenesis. Proc Natl Acad Sci USA 2004;101:12555-12560. (Pubitemid 39122062)
37. Marie PJ, Coffin JD, Hurley MM: FGF and FGFR signaling in chondrodysplasias and craniosynostosis. J Cell Biochem 2005;96:888-896. (Pubitemid 41688715)
38. Eswarakumar VP, Lax I, Schlessinger J: Cellular signaling by fibroblast growth factor receptors. Cytokine Growth Factor Rev 2005;16:139-149. (Pubitemid 40616112)
39. Dailey L, Ambrosetti D, Mansukhani A, Basilico C: Mechanisms underlying differential responses to FGF signaling. Cytokine Growth Factor Rev 2005;16:233-247. (Pubitemid 40616120)
40. Lemonnier J, Hay E, Delannoy P, Lomri A, Modrowski D, Caverzasio J, Marie PJ: Role of N-cadherin and protein kinase C in osteoblast gene activation induced by the S252W fibroblast growth factor receptor 2 mutation in Apert craniosynostosis. J Bone Miner Res 2001;16:832-845. (Pubitemid 32332293)
41. Tanimoto Y, Yokozeki M, Hiura K, Matsumoto K, Nakanishi H, Matsumoto T, Marie PJ, Moriyama K: A soluble form of fibroblast growth factor receptor 2 (FGFR2) with S252W mutation acts as an efficient inhibitor for the enhanced osteoblastic differentiation caused by FGFR2 activation in Apert syndrome. J Biol Chem 2004;279:45926-45934. (Pubitemid 39491585)
42. Baroni T, Carinci P, Lilli C, Bellucci C, Aisa MC, Scapoli L, Volinia S, Carinci F, Pezzetti F, Calvitti M, Farina A, Conte C, Bodo M: P253R fibroblast growth factor receptor-2 mutation induces RUNX2 transcript variants and calvarial osteoblast differentiation. J Cell Physiol 2005;202:524-535. (Pubitemid 40041324)
43. Fragale A, Tartaglia M, Bernardini S, Michela Di Stasi AM, Di Rocco C, Velardi F, Teti A, Battaglia PA, Migliacco S: Decreased proliferation and altered differentiation in osteoblasts from genetically and clinically distinct craniosynostotic disorders. Am J Pathol 1999;154:1465-1477. (Pubitemid 29226442)
44. Lomri A, Lemonnier J, Delannoy P, Marie PJ: Increased expression of protein kinase Calpha, interleukin-1alpha, and RhoA guanosine 5'-triphosphatase in osteoblasts expressing the Ser252Trp fibroblast growth factor 2 receptor Apert mutation: identification by analysis of complementary DNA microarray. J Bone Miner Res 2001;16:705-712. (Pubitemid 32230599)
45. Debiais F, Lemonnier J, Hay E, Delannoy P, Caverzasio J, Marie PJ: Fibroblast growth factor-2 (FGF-2) increases N-cadherin expression through protein kinase C and Src-kinase pathways in human calvaria osteoblasts. J Cell Biochem 2001;81:68-81.
46. Delannoy P, Lemonnier J, Haÿ E, Modrowski D, Marie PJ: Protein kinase C-dependent upregulation of N-cadherin expression by phorbol ester in human calvaria osteoblasts. Exp Cell Res 2001;269:154-161. (Pubitemid 32848498)
47. Lemonnier J, Delannoy P, Hott M, Lomri A, Modrowski D, Marie PJ: The Ser252Trp fibroblast growth factor receptor-2 (FGFR-2) mutation induces PKC-independent downregulation of FGFR-2 associated with premature calvaria osteoblast differentiation. Exp Cell Res 2000;256:158-167. (Pubitemid 30211178)
48. Hochstrasser M: Ubiquitin, proteasomes, and the regulation of intracellular protein degradation. Curr Opin Cell Biol 1995;7:215-223.
49. Ciechanover A: Intracellular protein degradation: from a vague idea thru the lysosome and the ubiquitin-proteasome system and onto human diseases and drug targeting. Cell Death Differ 2005;12:1178-1190.
50. Sanjay A, Horne WC, Baron R: The Cbl family: ubiquitin ligases regulating signaling by tyrosine kinases. Sci STKE 2001;110:PE40.
51. Wong A, Lamothe B, Lee A, Schlessinger J, Lax I: FRS2 alpha attenuates FGF receptor signaling by Grb2-mediated recruitment of the ubiquitin ligase Cbl. Proc Natl Acad Sci USA 2002;99:6684-6689. (Pubitemid 34526193)
52. Kaabeche K, Lemonnier J, Le Mée S, Caverzasio J, Marie PJ: Cbl-mediated degradation of Lyn and Fyn induced by constitutive FGFR-2 activation supports osteoblast differentiation. J Biol Chem 2004;279:36259- 36267. (Pubitemid 39128962)
53. Fromigue O, Modrowski D, Marie PJ: Apoptosis in membranous bone formation: role of fibroblast growth factor and bone morphogenetic protein signaling. Crit Rev Eukaryot Gene Expr 2005;15:75-92. (Pubitemid 40703953)
54. Xing L, Boyce BF: Regulation of apoptosis in osteoclasts and osteoblastic cells. Biochem Biophys Res Commun 2005;328:709-720. (Pubitemid 40208308)
55. Rice D, Kim H, Thesleff I: Apoptosis in murine calvarial bone and suture development. Eur J Oral Sci 1999;107:265-275.
56. Debiais F, Lefèvre G, Lemonnier J, Le Mée S, Lasmoles F, Mascarelli F, Marie PJ: Fibroblast growth factor-2 induces osteoblast survival through a phosphatidylinositol 3-kinase-dependent, -β-catenin-independent signaling pathway. Exp Cell Res 2004;297:235-246. (Pubitemid 38759576)
57. Lemonnier J, Haÿ E, Delannoy P, Fromigué O, Lomri A, Modrowski M, Marie PJ: Increased osteoblast apoptosis in Apert craniosynostosis: role of protein kinase C and interleukin-1. Am J Pathol 2001;158:1833-1842. (Pubitemid 32422948)
58. Kaabeche K, Guenou G, Bouvard D, Didelot N, Listrat A, Marie PJ: Cbl-mediated ubiquitination of alpha 5 integrin subunit mediates fibronectin-dependent osteoblast detachment and apoptosis induced by FGFR2 activation. J Cell Sci 2005;118:1223-1232. (Pubitemid 40528692)
59. Chen ZF, Behringer RR: Twist is required in head mesenchyme for cranial neural tube morphogenesis. Genes Dev 1995;9:686-699.
60. Johnson D, Iseki S, Wilkie AO, Morriss-Kay GM: Expression patterns of Twist and Fgfr1, -2 and -3 in the developing mouse coronal suture suggest a key role for twist in suture initiation and biogenesis. Mech Dev 2000;91:341-345. (Pubitemid 30125935)
61. Howard TD, Paznekas WA, Green ED, Chiang LC, Ma N, Ortiz De Luna RI, Garcia Delgado C, Gonzales-Ramos M, Kline AD, Jabs EW: Mutations in Twist, a basic helix-loop-helix transcription factor, in Saethre-Chotzen syndrome. Nat Genet 1997;15:36-41. (Pubitemid 27014947)
62. El Ghouzzi V, Le Merrer M, Perrin-Schmitt F, Lajeunie E, Benit P, Renier DC, Gonzales-Ramos M, Kline AD, Jabs EW: Mutations in Twist, a basic helix-loop-helix transcription factor, in Saethre-Chotzen syndrome. Nat Genet 1997;15:36-41. (Pubitemid 27014947)
63. Gripp K, Zackai E, Stolle C: Mutations in the human Twist gene. Hum Mut 2000;15:150-155. (Pubitemid 30078405)
64. El Ghouzzi V, Lajeunie E, Le Merrer M, Cormier-Daire V, Renier D, Munnich A, Bonaventure J: Mutations within or upstream of the basic helix-loop-helix domain of the Twist gene are specific to Saethre-Chotzen syndrome. Eur J Hum Genet 1999;7:27-33. (Pubitemid 29179029)
65. El Ghouzzi V, Legeai-Mallet L, Aresta S, Benoist C, Munnich A, de Gunzburg J, Bonaventure J: Saethre-Chotzen mutations cause Twist protein degradation or impaired nuclear location. Hum Mol Genet 2000;9:813-819. (Pubitemid 30162766)
66. El Ghouzzi V, Legeai-Mallet L, Benoist-Lasselin C, Lajeunie E, Renier D, Munnich A, Bonaventure J: Mutations in the basic domain and the loop-helix II junction of Twist abolish DNA binding in Saethre-Chotzen syndrome. FEBS Lett 2001;492:112-118. (Pubitemid 32206730)
67. Yousfi M, Lasmoles F, Marie PJ: TWIST inactivation reduces CBFA1/RUNX2 expression and DNA binding to the osteocalcin promoter in osteoblasts. Biochem Biophys Res Commun 2002;297:641-644.
68. Jabs EW: A TWIST in the fate of human osteoblasts identifies signaling molecules involved in skull development. J Clin Invest 2001;107:1075-1077. (Pubitemid 32422902)
69. Bialek P, Kern B, Yang X, Schrock M, Sosic D, Hong N, Wu H, Yu K, Ornitz DM, Olson EN, Justice MJ, Karsenty G: A twist code determines the onset of osteoblast differentiation. Dev Cell 2004;6:423-435. (Pubitemid 38364573)
70. Rice DP, Aberg T, Chan Y, Tang Z, Kettunen PJ, Pakarinen L, Maxson RE, Thesleff I: Integration of FGF and TWIST in calvarial bone and suture development. Development 2000;127:1845-1855. (Pubitemid 30311788)
71. Guenou H, Kaabeche K, Le Mee S, Marie PJ: A role for fibroblast growth factor receptor-2 in the altered osteoblast phenotype induced by Twist haploinsufficiency in the Saethre-Chotzen syndrome. Hum Mol Genet 2005;14:1429-1439. (Pubitemid 40823453)
72. Maestro R, Dei Tos AP, Hamamori Y, Krasnokutsky S, Sartorelli V, Kedes L, Doglioni C, Beach DH, Hannon GJ: Twist is a potential oncogene that inhibits apoptosis. Genes Dev 1999;13:2207-2217. (Pubitemid 29426726)
73. Dupont J, Fernandez AM, Glackin CA, Helman L, LeRoith D: Insulin-like growth factor 1 (IGF-1) - induced twist expression is involved in the anti-apoptotic effects of the IGF-1 receptor. J Biol Chem 2001;276:26699-26707.
74. Yousfi M, Lasmoles F, El Ghouzzi V, Marie PJ: Twist haploinsufficiency in Saethre-Chotzen syndrome induces calvaria osteoblast apoptosis due to increased TNFalpha expression and caspase-2 activation. Hum Mol Genet 2002;11:359-369. (Pubitemid 34213609)
75. Sosic D, Richardson JA, Yu K, Ornitz DM, Olson EN: Twist regulates cytokine gene expression through a negative feedback loop that represses NF-kappaB activity. Cell 2003;112:169-180. (Pubitemid 36144107)
76. Mansukhani A, Ambrosetti D, Holmes G, Cornivelli L, Basilico C: Sox2 induction by FGF and FGFR2 activating mutations inhibits Wnt signaling and osteoblast differentiation. J Cell Biol 2005;168:1065-1076.